Clinical Psychopharmacology and Neuroscience

Korean College of Neuropsychopharmacology (대한정신약물학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Usefulness of Aripiprazole Treatment in a Girl with Prader-Willi Syndrome and Psychosis

  • Briegel, Wolfgang (Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Leopoldina Hospital)
  • Received : 2017.02.07
  • Accepted : 2017.05.10
  • Published : 2018.11.30
⟨ Previous Next ⟩

Abstract

Prader-Willi syndrome (PWS) is a quite rare multi-systemic genetic disorder strongly associated with psychiatric illness in adults, especially psychosis. This report presents a 16-year-old female with PWS and symptoms of brief psychotic disorder with a complete resolution of symptoms under aripiprazole medication. However, an exacerbation occurred after aripiprazole reduction. Apart from a weight gain of about 2 kg over the course of two years, no adverse effects could be found. This first report on the use of aripiprazole in a subject with PWS and psychosis suggests that aripiprazole might be a promising treatment approach in this distinct group of patients.

Keywords

References

  1. Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet 2009;17:3-13. https://doi.org/10.1038/ejhg.2008.165
  2. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest 2015;38:1249-1263. https://doi.org/10.1007/s40618-015-0312-9
  3. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi syndrome. 1998 Oct 6 [updated 2016 Feb 4, cited 2017 Nov 10]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. $GeneReviews^{(R)}$ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1330/
  4. Ho AY, Dimitropoulos A. Clinical management of behavioral characteristics of Prader-Willi syndrome. Neuropsychiatr Dis Treat 2010;6:107-118.
  5. Sinnema M, Boer H, Collin P, Maaskant MA, van Roozendaal KE, Schrander-Stumpel CT, et al. Psychiatric illness in a cohort of adults with Prader-Willi syndrome. Res Dev Disabil 2011;32:1729-1735. https://doi.org/10.1016/j.ridd.2011.02.027
  6. Bonnot O, Cohen D, Thuilleaux D, Consoli A, Cabal S, Tauber M. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature. Eur J Pediatr 2016;175:9-18.
  7. Benjamin E, Buot-Smith T. Naltrexone and fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:870-873. https://doi.org/10.1097/00004583-199307000-00025
  8. Akca OF, Yilmaz S. Aripiprazole in the treatment of obsessive compulsive disorder and aggressive behaviors in a child with Prader Silli syndrome: a case report. J Clin Psychopharmacol 2016;36:526-528. https://doi.org/10.1097/JCP.0000000000000566
  9. Herguner S, Mukaddes NM. Psychosis associated with fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 2007;46:944-945. https://doi.org/10.1097/chi.0b013e318068fbed
  10. Kohn Y, Weizman A, Apter A. Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine. Int J Eat Disord 2001;30:113-117. https://doi.org/10.1002/eat.1062
  11. Dech B, Budow L. The use of fluoxetine in an adolescent with Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 1991;30:298-302. https://doi.org/10.1097/00004583-199103000-00020
  12. Araki S, Ohji T, Shiota N, Dobashi K, Shimono M, Shirahata A. Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome. Pediatr Int 2010;52:e1-e3. https://doi.org/10.1111/j.1442-200X.2009.02996.x
  13. Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J. Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatr Scand 2000;102:461-465. https://doi.org/10.1034/j.1600-0447.2000.102006461.x
  14. Kaufman AS, Kaufman NL. Kaufman assessment battery for children K-ABC. 8th ed. German version by Melchers P and Preuss U. Frankfurt am Main:Pearson Assessment;2009.
  15. Yang L, Zhan GD, Ding JJ, Wang HJ, Ma D, Huang GY, et al. Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects--a meta analysis. PLoS One 2013;8:e72640. https://doi.org/10.1371/journal.pone.0072640
  16. Lo ST, Collin PJ, Hokken-Koelega AC. Psychiatric disorders in children with Prader-Willi syndrome-Results of a 2-year longitudinal study. Am J Med Genet A 2015;167A:983-991.
  17. Briegel W. Neuropsychiatric aspects of Prader-Willi syndrome-a review. Z Kinder Jugendpsychiatr Psychother 2017;14:1-8.
  18. Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci 2015;9:297.
  19. Safer DJ, Calarge CA, Safer AM. Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol 2013;23:282-289. https://doi.org/10.1089/cap.2012.0062
  20. Soni S, Whittington J, Holland AJ, Webb T, Maina EN, Boer H, et al. The phenomenology and diagnosis of psychiatric illness in people with Prader-Willi syndrome. Psychol Med 2008;38:1505-1514. https://doi.org/10.1017/S0033291707002504

Cited by

  1. Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report vol.17, pp.1, 2018, https://doi.org/10.9758/cpn.2019.17.1.130
  2. Benefits of multidisciplinary care in Prader-Willi syndrome vol.16, pp.2, 2018, https://doi.org/10.1080/17446651.2021.1898375